The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance
Open accessAbstract
// G.S. Falchook 1 , J.C. Trent 2 , M.C. Heinrich 3 , C. Beadling 3 , J. Patterson 3 , C.C. Bastida 1 , S.C. Blackman 4 , R. Kurzrock 5 1 Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 2 Sarcoma Medical Oncology Program, University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida 3 Portland VA Medical Center and Oregon Health & Science University (OHSU) Knight Cancer Institute, Division of Hematology & Oncology, Portland, Oregon 4 GlaxoSmithKline, Collegeville, PA 5 Moores Cancer Center, Department of Medicine, Hematology-Oncology Division, The University of California, San Diego, La Jolla, CA Correspondence: Gerald Falchook, email: // Keywords : Gastrointestinal stromal tumor, Dabrafenib, GSK2118436, BRAF mutation, BRAF inhibition, V600E Received : February 8, 2013 Accepted : February 24, 2013 Published : February 25, 2013 Abstract Activating oncogenic mutations of BRAF have been described in patients with gastrointestinal stromal tumor (GIST), but treatment of GIST with BRAF inhibitors and mechanisms of mediating the emergence of resistance in GIST have not been reported. Dabrafenib is a potent ATP-competitive inhibitor of BRAF kinase and is highly selective for mutant BRAF in kinase panel screening, cell lines, and xenografts. We report prolonged antitumor activity in the first patient with V600E BRAF-mutated GIST who was treated with a BRAF inhibitor. Whole exome sequencing performed in tumor tissue obtained at the time of progressive disease demonstrated a somatic gain-of-function PIK3CA mutation (H1047R) as well as a CDKN2A aberration, which may have contributed to eventual resistance to treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A method and server for predicting damaging missense mutations.
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010) · Nature Methods · doi:10.1038/nmeth0410-248 · Cited by 13,194 · cited 1×
“Nucleotide variants were translated, and non-synonymous variants were identified using SIFT[23], PolyPhen2[24], and Mutation Assessor[25].”
MethodMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 2×
“The most common BRAF mutation is a substitution of valine with glutamic acid at amino acid position 600 (V600E), which locks BRAF into its active conformation, resulting in a ten-fold increase in activity over wild-type BRAF[17].”
BackgroundIntratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Kumar, P., Henikoff, S., & Ng, P. C. (2009) · Nature Protocols · doi:10.1038/nprot.2009.86 · Cited by 6,521 · cited 2×
“Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm.”
MethodEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Self-citationRAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454 · cited 1×
“We further tested RNA from all three lesions and were unable to detect aberrant BRAF splicing as a basis for drug resistance[22].”
Cited by
Casali, P. G., Abecassis, N., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brodowicz, T., Broto, J. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy095 · Cited by 750
Casali, P. G., Blay, J. Y., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.005 · Cited by 605
Gastrointestinal stromal tumours
Blay, J.-Y., Kang, Y.-K., Nishida, T., & von Mehren, M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00254-5 · Cited by 460
Boikos, S. A., Pappo, A. S., Killian, J. K., LaQuaglia, M. P., Weldon, C. B., George, S., Trent, J. C., von Mehren, M., Wright, J. A., Schiffman, J. D., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0256 · Cited by 416
Self-citation
Metadata
- Authors
- Falchook, G. S., Trent, J. C., Heinrich, M. C., Beadling, C., Patterson, J., Bastida, C. C., Blackman, S. C., & Kurzrock, R.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2013-02-25
- Volume
- 4
- Issue
- 2
- Pages
- 310-315
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2157539391
- Cited by
- 169
- References
- 7
- FWCI
- 14.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.